ArticleTheranostics2026

A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4.

Rae-Kwon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.